Belatacept‐Based Immunosuppression and Donor‐Specific Antibodies in Lung Transplant: A Multi‐Institutional Retrospective Study
Clinical Transplantation · 2025
DOI: 10.1111/ctr.70415 ↗At a glance
Multizentrische Studie in Clinical Transplantation, 2025. Written by Moustafa Younis and 14 co-authors. Institution: Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida, Gainesville, Florida, USA. Major MEDLINE topics: Abatacept, Graft Rejection, Immunosuppressive Agents, Isoantibodies. 26 references.
Abstract (original language)
Background
Belatacept use in renal transplant is associated with similar graft survival and elimination of preexisting donor‐specific antibodies (DSA). We aim to describe the impact of Belatacept use on de novo DSA in lung transplant (LTx).
Methods
A multi‐institutional retrospective review of LTx patients with de novo DSA who received Belatacept (January 2018–August 2023) was performed. The primary outcome is the change in DSA post Belatacept initiation. Changes in mean fluorescence intensity (MFI) before and after Belatacept administration were analyzed using a linear mixed‐effects model. Secondary outcomes included antibody‐mediated rejection (AMR).
Results
Forty‐four patients with DSA received Belatacept. Most DSA were class II ( n = 41, 93%), with a median (IQR) MFI of 4000 (2500–7000) at Belatacept initiation. Following Belatacept initiation, DSA resolved in ( n = 25, 57%) patients, decreased in ( n = 7, 16%), and remained unchanged in ( n = 12, 27%). No de novo DSA developed during Belatacept therapy. There was no significant change in MFI pre Belatacept administration (change = −38, 95% CI: −267 to 191, p = 0.745), whereas MFI decreased significantly post Belatacept administration (change = −334, 95% CI: −449 to −219, p < 0.001). A total of ( n = 25, 57%) patients experienced AMR prior to initiating Belatacept. None of the patients developed AMR while on Belatacept.
Conclusion
This is the largest cohort to date of LTx patients with DSA who received Belatacept. Belatacept use was associated with a reduction in DSA.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Florida, Gainesville, Florida, USA.
- Division of Pulmonary and Critical Care, Department of Medicine, UT Southwestern, Dallas, Texas, USA.
- Division of Thoracic Surgery, Department of Surgery, University of Florida, Gainesville, Florida, USA.
ORCID profiles: Moustafa Younis, Vaidehi Kaza
Cite
APA
Younis, M., Mederos, C. I., Miller, C. M., Kumar, P., Ishaq, A., Mu, A., Gries, C., Reams, V., Aladaileh, M. A., Rackauskas, M., Kaza, V., Bollineni, S., Torres, F., Emtiazjoo, A., & Timofte, I. (2025). Belatacept‐Based Immunosuppression and Donor‐Specific Antibodies in Lung Transplant: A Multi‐Institutional Retrospective Study. Clinical Transplantation. https://doi.org/10.1111/ctr.70415
Vancouver
Younis M, Mederos CI, Miller CM, Kumar P, Ishaq A, Mu A, et al. Belatacept‐Based Immunosuppression and Donor‐Specific Antibodies in Lung Transplant: A Multi‐Institutional Retrospective Study. Clinical Transplantation. 2025. doi:10.1111/ctr.70415
BibTeX
@article{Younis2025,
author = {Younis, Moustafa and Mederos, Christopher I and Miller, Cecelia M and Kumar, Pooja and Ishaq, Ariana and Mu, Amy and Gries, Cynthia and Reams, Victoria and Aladaileh, Mohammad A and Rackauskas, Mindaugas and Kaza, Vaidehi and Bollineni, Srinivas and Torres, Fernando and Emtiazjoo, Amir and Timofte, Irina},
title = {Belatacept‐Based Immunosuppression and Donor‐Specific Antibodies in Lung Transplant: A Multi‐Institutional Retrospective Study},
journal = {Clinical Transplantation},
year = {2025},
doi = {10.1111/ctr.70415}
}
EUVIMED